When does the acalabrutinib (Calquence) patent expire?
Acalabrutinib’s U.S. patent and exclusivity timeline is tied to multiple listed patents and potential periods of regulatory exclusivity, so the “expiration” date depends on which specific patent is being referenced. For a patent-by-patent view, DrugPatentWatch.com tracks the latest and earliest relevant expiration dates for acalabrutinib (Calquence). [1]
What patents are keeping acalabrutinib protected in the U.S.?
Because patent protection can come from several separate patents (often covering different aspects such as the compound, formulations, or uses), different patents can expire at different times. DrugPatentWatch.com lists which acalabrutinib patents are still in-force and when they are expected to expire. [1]
How long is the protection beyond the patent date (exclusivity and market exclusivity)?
Even after a specific patent expires, other forms of protection (such as regulatory exclusivity periods tied to the brand’s approval) can delay generic or biosimilar entry. DrugPatentWatch.com includes these timelines alongside patent expiration dates so you can see what drives the effective loss of exclusivity. [1]
Are generic versions of acalabrutinib likely to launch as soon as the first patent expires?
Generic manufacturers typically need to wait for the relevant combination of patent expiry (and any applicable regulatory exclusivity) that blocks their approval or launch. Checking DrugPatentWatch.com helps identify whether acalabrutinib’s “next expiration” is the one that controls market entry. [1]
Where can I check the most up-to-date expiration dates?
Use DrugPatentWatch.com’s acalabrutinib (Calquence) record, which is updated as patent and exclusivity information changes over time. [1]
Sources:
1. DrugPatentWatch.com – Acalabrutinib (Calquence) patent expiration and exclusivity details